Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s ...
The Dementia Trials Accelerator (DTA) – which will be spearheaded by the UK Dementia Research Institute (UK DRI) and Health ...
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
Bybit, the world's second-largest cryptocurrency exchange by trading volume, announces the WSOT Copy Trading Fest, inviting ...
Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancerPositive interim Phase 1 data evaluating ALG.APV-527 monotherapy in multiple solid tumor ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...
Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback